This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT493 + ABT-530
Description: ABT-493/ABT-530 is a combination of next-generation hepatitis c virus (HCV) protease inhibitor ABT-493 and ABT-530, a non-structural 5A protein inhibitor.
Enanta and Abbvie
ABT-493 was developed by Enanta in collaboration with AbbVie.
In December 2006, Enanta and Abbott formed a worldwide alliance for the development of protease inhibitors. Upon closing, Enanta received an upfront payment of $57 million, which included a cash payment and an equity investment. If all potential clinical and regulatory milestones are met, additional payments of up to $250 million will be made to Enanta, and further payments will be due if multiple products develop from the program. Enanta will receive double-digit royalties and holds an option to fund 40 percent of development costs and U.S. commercialization efforts (sales and promotion costs) in exchange for a 40-percent profit share in the United States on medicines from this alliance that result in commercial approval.
In October 2014, Enanta announced that it has decided not to exercise its co-development option for ABT-493 for hepatitis C virus (HCV) being developed in...See full deal structure in Biomedtracker
Partners: Enanta Pharmaceuticals, Inc.
Additional information available to subscribers only: